185692-51-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzyl-hexahydro-cyclopenta[c]pyrrol-4-one is used as a precursor in the synthesis of other pharmaceuticals for its ability to contribute to the development of new medications with potential therapeutic applications.
Used in Pain Management:
2-Benzyl-hexahydro-cyclopenta[c]pyrrol-4-one is used as an analgesic agent for its pain-relieving properties, offering a potential treatment option for various types of pain conditions.
Used in Neurological Treatments:
2-Benzyl-hexahydro-cyclopenta[c]pyrrol-4-one is used as an anticonvulsant in neurological treatments to help manage conditions such as epilepsy and other seizure disorders, providing an alternative therapeutic approach to control convulsions and seizures.

Upstream product

• 930-30-3 cyclopent-2-enone 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 

Downstream Products

• 122828-28-8 2-benzylhexahydrocyclopenta[C]pyrrole-4-(1H)-one oxime 
• 879686-39-2 2-benzyl-6-chloro-1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrole-5-carbaldehyde 
• 1228029-77-3 racemic-(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ol 
• 939028-77-0 C₂₆H₃₄N₂O 
• 939032-90-3 C₂₈H₄₁NO₂Si 
• 1228029-73-9 (S)-N-[(3aR,4E,6aS)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-ylidene]-2-methylpropane-2-sulfinamide 
• 1228029-74-0 (S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamide 
• 879686-42-7 4-oxohexahydrocyclopenta[c]pyrrole-2-carboxylic acid tert-butyl ester 
• 851526-87-9 2-benzylhexahydro-1H-pyrrolo[3,4-c]pyridine-4(2H)-one 
• 130658-13-8 racemic-tert-butyl (3aS*,4S*,6aR*)-4-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 

Relevant academic research and scientific papers

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Moxifloxacin of a kind of hydrochloric acid and its preparation method like structure

The invention provides a novel moxifloxacin hydrochloride structural analog 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-oxo hexahydro-1H-pyrrolo[3,4-c] pyridine-6(2H)yl)-1,4-dihydroquinoline-3-carboxylic acid (I), a preparation method of the analog, and a

3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS

The invention relates to novel heteroaromatic derivatives of formula (I) and their addition salts thereof with acids and bases; their preparation, their use as drugs and pharmaceutical compositions and associations containing them. wherein A, B, T, V, X and Y represent organic substituents as defined herein, The compounds of formula (I) are able to inhibit the activity of the Gram-positive bacterial DltA enzyme and they are used to prevent and/or treat Gram-positive bacterial infections in humans or animals, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity,

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Tricyclic amine derivatives

The present invention relates to a compound having a tricyclic amine substituent which may have various substituents, the compound being represented by formula (I), a salt or hydrate thereof, and a hydrate of the salt and a drug containing them as an acti